Anushiravani Majid, Manteghi Ali A, Taghipur Ali, Eslami Mahdi
Department of Persian Medicine, School of Persian and Complementary Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Curr Drug Discov Technol. 2019;16(2):232-238. doi: 10.2174/1570163815666180219115844.
According to new studies, only 60% of depressed patients respond to pharmaceutical treatment while suffering from their side effects. Natural products as adjuvant or alternative therapies should be examined to find safer and more effective ways to cope with depression.
To find out the potential benefits of a combined herbal drug based on Echium amoenum compared with citalopram in the treatment of Major Depressive Disorder.
In psychiatry clinics of Mashhad University of Medical Sciences, 50 patients who met the criteria for Major Depressive Disorder based on DSM-5 were studied in a parallel randomized controlled trial.
Subjects were randomly assigned to receive Echium amoenum compound syrup (EACS) or citalopram tablet for 8 weeks.
The efficacy of treatments and recurrence of disease were surveyed and compared according to Hamilton depression rating scale at weeks 0, 4, 8, 12.
Patients in both groups of citalopram and EACS showed remarkable reduction in scores of Hamilton questionnaire. At the eighth week of treatment, the mean scores in EACS group were significantly lower than citalopram group (p-value = 0.03). 52% of patients suffered from various complications in citalopram group while just 12% of patients in EACS group reported few complications.
Clinical efficacy of this herbal drug was significantly higher than citalopram, and complications were also less and lower in EACS group. Further studies with larger groups and para-clinical assessments such as serologic tests and QEEG would improve our understanding of the impacts and mechanisms of EACS.
根据新的研究,只有60%的抑郁症患者在接受药物治疗时有效,但同时会遭受副作用。应研究天然产物作为辅助或替代疗法,以找到更安全、更有效的方法来应对抑郁症。
研究基于蓝蓟的复方草药与西酞普兰相比,在治疗重度抑郁症方面的潜在益处。
在马什哈德医科大学的精神病学诊所,对50名符合DSM-5中重度抑郁症标准的患者进行了一项平行随机对照试验。
受试者被随机分配接受蓝蓟复方糖浆(EACS)或西酞普兰片,为期8周。
在第0、4、8、12周,根据汉密尔顿抑郁量表对治疗效果和疾病复发情况进行调查和比较。
西酞普兰组和EACS组患者的汉密尔顿问卷得分均显著降低。在治疗的第八周,EACS组的平均得分显著低于西酞普兰组(p值 = 0.03)。西酞普兰组52%的患者出现各种并发症,而EACS组只有12%的患者报告有少量并发症。
这种草药药物的临床疗效显著高于西酞普兰,且EACS组的并发症也更少、更轻。通过更大规模的研究以及血清学检测和脑电地形图等临床前评估,将有助于我们更好地理解EACS的作用和机制。